Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Antimicrobial Resistance Diagnostics Market, by Technology
1.4.2 North America Antimicrobial Resistance Diagnostics Market, by End User
1.4.3 North America Antimicrobial Resistance Diagnostics Market, by Pathogen
1.4.4 North America Antimicrobial Resistance Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
Chapter 4. North America Antimicrobial Resistance Diagnostics Market by Technology
4.1 North America PCR Market by Country
4.2 North America Immunoassay Market by Country
4.3 North America NGS Market by Country
4.4 North America Microbiology Culture Market by Country
4.5 North America Mass Spectrometry Market by Country
4.6 North America Rapid & Point of Care Market by Country
4.7 North America Others Market by Country
Chapter 5. North America Antimicrobial Resistance Diagnostics Market by End-user
5.1 North America Hospitals Market by Country
5.2 North America Diagnostic Laboratories Market by Country
5.3 North America Pharmaceutical, Biotechnology Companies & Others Market by Country
Chapter 6. North America Antimicrobial Resistance Diagnostics Market by Pathogen
6.1 North America Methicillin Resistant Staphylococcus Aureus (MRSA) Market by Country
6.2 North America Clostridium Difficile (CD) Market by Country
6.3 North America Drug Resistant Campylobacter (DRC) Market by Country
6.4 North America Drug Resistant Streptococcus Pneumoniae (DRSP) Market by Country
6.5 North America Drug Resistant Neisseria Gonorrhoeae (DRNG) Market by Country
6.6 North America Drug Resistant Salmonella (DRNTS) Market by Country
6.7 North America Others Market by Country
Chapter 7. North America Antimicrobial Resistance Diagnostics Market by Country
7.1 US Antimicrobial Resistance Diagnostics Market
7.1.1 US Antimicrobial Resistance Diagnostics Market by Technology
7.1.2 US Antimicrobial Resistance Diagnostics Market by End-user
7.1.3 US Antimicrobial Resistance Diagnostics Market by Pathogen
7.2 Canada Antimicrobial Resistance Diagnostics Market
7.2.1 Canada Antimicrobial Resistance Diagnostics Market by Technology
7.2.2 Canada Antimicrobial Resistance Diagnostics Market by End-user
7.2.3 Canada Antimicrobial Resistance Diagnostics Market by Pathogen
7.3 Mexico Antimicrobial Resistance Diagnostics Market
7.3.1 Mexico Antimicrobial Resistance Diagnostics Market by Technology
7.3.2 Mexico Antimicrobial Resistance Diagnostics Market by End-user
7.3.3 Mexico Antimicrobial Resistance Diagnostics Market by Pathogen
7.4 Rest of North America Antimicrobial Resistance Diagnostics Market
7.4.1 Rest of North America Antimicrobial Resistance Diagnostics Market by Technology
7.4.2 Rest of North America Antimicrobial Resistance Diagnostics Market by End-user
7.4.3 Rest of North America Antimicrobial Resistance Diagnostics Market by Pathogen
Chapter 8. Company Profiles
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 Becton, Dickinson and Company
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.3 BioMérieux S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition, Joint Ventures and Mergers:
8.4 F. Hoffmann-La Roche Ltd.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Acquisition and Mergers:
8.5 Danaher Corporation
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Hologic, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Financial Analysis
8.6.4 Segmental and Regional Analysis
8.6.5 Recent strategies and developments:
8.6.5.1 Product Launches and Product Expansions:
8.6.5.2 Acquisition and Mergers:
8.7 Vela Diagnostics Pte. Ltd. (Luye Medical Group Co., Ltd)
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Product Launches and Product Expansions:
8.8 Molsid SAS
8.8.1 Company Overview
8.9 Visby Medical, Inc.
8.9.1 Company Overview
8.10. Accelerated Technology Laboratories, Inc.
8.10.1 Company Overview
Unique Offerings 
